Data / Form D filings / Gelesis Inc
Gelesis Inc: Form D filings
Gelesis Inc, a biotechnology company in Boston, MA, filed 3 Form D notices with the SEC between 2011 and 2015. The latest, on December 30, 2015, reports $31.5 million sold of a $34 million offering to 6 investors.
Find out what Gelesis Inc does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 501 BOYLSTON STREET, SUITE 6102, Boston, MA, 02116
- Phone
- (617) 456-4718
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1385374
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 30, 2015 | New notice | $33,999,981 | $31,499,980 | $2,500,001 | 6 | Dec 17, 2015 | sec.gov |
| Jun 9, 2011 | New notice | $2,555,000 | $2,555,000 | $0 | 11 | May 25, 2011 | sec.gov |
| May 12, 2011 | New notice | $3,638,696 | $3,638,696 | $0 | 19 | Apr 30, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Meghan Fitzgerald | Director | |
| John LaMattina | Director | |
| Elon Boms | Director | |
| Robert Forrester | Director | |
| Yishai Zohar | Executive Officer, Director | |
| Elliot Maltz | Executive Officer |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
- Axelyf, Inc. $2.6 million · Oct 13, 2026
- BIOVENTRIX, INC. $1.2 million · Oct 8, 2026
- Opus KSD, Inc. $680,801 · Oct 1, 2026
- Xact Bio, Inc. $10 million · Sep 28, 2026
- Way Biosolutions, Inc. $2 million · Sep 25, 2026
- AutoIVF, Inc. $1.5 million · Sep 25, 2026
- Typewriter Therapeutics, Inc. $56.3 million · Sep 21, 2026
Every Form D from the week of Dec 28, 2015 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Gelesis Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.